Correlations between the expression levels of micro-RNA146b, 221, 222 and p27Kip1 protein mRNA and the clinicopathologic parameters in papillary thyroid cancers

Experimental and Clinical Endocrinology and Diabetes

Volumn 122, Issue 3, 2014, Pages 137-143

  Acibucu, F ^a   Dokmetas H S ^a   Tutar, Y ^a   Elagoz, S ^a   Kilicli, F ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Hashimoto's thyroiditis; MiRNAs; thyroid cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICRORNA; MICRORNA 146B; MICRORNA 221; MICRORNA 222; UNCLASSIFIED DRUG; CDKN1B PROTEIN, HUMAN; MESSENGER RNA; MIRN146 MICRORNA, HUMAN; MIRN221 MICRORNA, HUMAN; MIRN222 MICRORNA, HUMAN; RNA;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER RISK; CERVICAL LYMPH NODE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENETIC ASSOCIATION; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; THYROID CANCER; TUMOR INVASION; AGED; BIOSYNTHESIS; GENETICS; METABOLISM; PAPILLARY CARCINOMA; THYROID TUMOR;

ADULT; AGED; CARCINOMA, PAPILLARY; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HASHIMOTO DISEASE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; RNA, MESSENGER; RNA, NEOPLASM; THYROID NEOPLASMS;

EID: 84896482818     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0034-1367025     Document Type: Article

References (35)

1. Tai P., Mould R. F., Prysyazhnyuk A. Y. et al. Descriptive epidemiology of thyroid carcinoma. Current Oncology: 2003; 10 54 65 (Pubitemid 36578399)
2. Hofman V., Lassalle S., Bonnetaud C. et al. Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility. Virchows Arch: 2009; 455 21 33
3. Chou C. K., Chen R. F., Chou F. F. et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF (V600E) mutation. Thyroid: 2010; 20 489 494
4. Shenouda S. K., Alahari S. K. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev: 2009; 28 369 378
5. Eckstein F. Small non-coding RNAs as magic bullets. Trends Biochem Sci: 2005; 30 445 452 (Pubitemid 41033240)
6. Mattick J. S., Makunin I. V. Small regulatory RNAs inmammals. Hum Mol Genet: 2005; 14 R121 R132
7. Ambros V. The functions of animal microRNAs. Nature: 2004; 431 350 355 (Pubitemid 39265675)
8. Calin G. A., Dumitru C. D., Shimizu M. et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA: 2002; 99 15524 15529 (Pubitemid 35403967)
9. Iorio M. V., Ferracin M., Liu C. G. et al. MicroRNA gene expression deregulation inhuman breast cancer. Cancer Res: 2005; 65 7065 7070 (Pubitemid 41161233)
10. Metzler M., Wilda M., Busch K. et al. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer: 2004; 39 167 169 (Pubitemid 38056091)
11. Chan J. A., Krichevsky A. M., Kosik K. S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res: 2005; 65 6029 6033 (Pubitemid 40994386)
12. He H., Jazdzewski K., Li W. et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA: 2005; 102 19075 19080 (Pubitemid 43049568)
13. Takamizawa J., Konishi H., Yanagisawa K. et al. Reduced expression of the let-7 microRNAs in human lung cancers in association withshortened postoperative survival. Cancer Res: 2004; 64 3753 3756 (Pubitemid 38697282)
14. Hayashita Y., Osada H., Tatematsu Y. et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res: 2005; 65 9628 9632 (Pubitemid 41541436)
15. Murakami Y., Yasuda T., Saigo K. et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene: 2006; 25 2537 2545
16. Visone R., Russo L., Pallante P. et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer: 2007; 14 791 798 (Pubitemid 350074067)
17. Lu J., Getz G., Miska E. A. et al. MicroRNA expression profiles classify human cancers. Nature: 2005; 435 834 838 (Pubitemid 40839735)
18. Calin G. A., Liu C. G., Sevignani C. et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA: 2004; 101 11755 11760 (Pubitemid 39095368)
19. Calin G. A., Ferracin M., Cimmino A. et al. microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med: 2005; 353 1793 1801 (Pubitemid 41549891)
20. Eis P. S., Tam W., Sun L. et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA: 2005; 102 3627 3632 (Pubitemid 40354662)
21. Gao Y., Wang C., Shan Z. et al. miRNA expression in a human papillary thyroid carcinoma cell line varies with invasiveness. Endocr J: 2010; 57 81 86
22. Cooper D. S., Doherty G. M., Haugen B. R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid: 2009; 19 1167 1214
23. Pallante P., Visone R., Croce C. M. et al. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocr Relat Cancer: 2010; 17 F91 F104
24. Taganov K. D., Boldin M. P., Chang K. J. et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innateimmune responses. PNAS: 2006; 103 12481 12486 (Pubitemid 44267285)
25. Pallante P., Visone R., Ferracin M. et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocrine-Related Cancer: 2006; 13 497 508 (Pubitemid 43886672)
26. Chen Y. T., Kitabayashi N., Zhou X. K. et al. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol: 2008; 21 1139 1146
27. Sheu S. Y., Grabellus F., Schwertheim S. et al. Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. British Journal of Cancer: 2010; 102 376 382
28. Karube Y., Tanaka H., Osada H. et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci: 2005; 96 111 115 (Pubitemid 40425386)
29. Leboulleux S., Rubino C., Baudin E. et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab: 2005; 90 5723 5729 (Pubitemid 41415482)
30. Fero M. L., Rivkin M., Tasch M. et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell: 1996; 85 733 744
31. Slingerland J., Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. Journal of Cell Physiology: 2000; 183 10 17 (Pubitemid 30130220)
32. Cunha L. L., Ferreira R. C., Marcello M. A. et al. Clinical and pathological implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer. J Thyroid Res: 2011; 17 2011 387062
33. Papotti M., Rodriguez J., De Pompa R. et al. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumours with follicular architecture of uncertain malignant potential. Mod Pathol: 2005; 18 541 546 (Pubitemid 40478118)
34. Scognamiglio T., Hyjek E., Kao J. et al. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol: 2006; 126 700 708 (Pubitemid 44707620)
35. Fontaine J. F., Mirebeau-Prunier D., Franc B. et al. Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy. Oncogene: 2008; 27 2228 2236 (Pubitemid 351483376)